Objective: To determine whether the distribution of peripheral blood mononuclear cells (PBMCs) is altered in paraneoplastic opsoclonus-myoclonus (POM).
L
ymphocyte immunophenotyping by flow cytometry is now the preferred method of delineating lymphocyte distribution in human immunologic disorders. The presence of flow cytometers in most large medical facilities and the rapid return of test results make immunophenotyping an ideal tool when clinical decisions must be made promptly.
Paraneoplastic opsoclonus-myoclonus syndrome (POM) is one such putative immunologic disorder in need of attention. 1 Although the presence of the paraneoplastic syndrome is associated with enhanced survival from the underlying tumor, 2 which in children is usually neuroblastoma, 3 outcome is marred by persistent and serious neuropsychological problems. Immunologic modeling in POM has been put forth, 4 drawing on autoantibody data and other clues, 5 but much of the mechanism by which an onconeural antigen elicits the neurologic syndrome remains to be elucidated. Autoantibodies continue to be a focus of research in POM, 6, 7 but potential T-cell involvement, which is so important in many other autoimmune disorders, has been understudied.
We have been searching for biomarkers of disease activity, and the evolving story of lymphocyte involvement in POM led us to study lymphocyte subsets in peripheral blood. Recently, we found both T-cell and B-cell abnormalities in cerebrospinal fluid (CSF) in POM, 8 and we now set out to determine whether less intrusively obtained information from circulating peripheral blood mononuclear cells (PBMCs) is clinically useful in the disorder.
PATIENTS AND METHODS

Patients
Seventeen children with neuroblastoma and POM were recruited through the National Pediatric Myoclonus Center for screening by the principal investigator (M.R.P.) to establish eligibility and obtain consent for this institutional review boardapproved study. The clinical characteristics are shown in Table 1 .
All the patients had symptoms of active disease at the time of evaluation despite tumor resection. None had evidence of recurrent neuroblastoma using neuroimaging and blood and urine tumor markers. For those who had received chemotherapy, the mean length of time from completion of therapy was 10.3 6 4.1 (SEM) months. Due to the referral pattern to our national center for opsoclonus-myoclonus (OM), which accepts children at any stage in the course of their disorder, this was a cross-sectional study.
Controls
Two different kinds of control groups were used. Seventeen age-and gender-matched children with nonimmunologic and noninfectious neurologic disorders served as neurologic controls: they had neither OM nor neuroblastoma. Many had myoclonus or ataxia of other etiologies, controlling for these aspects of POM, and none of the children had ever received immunotherapy.
The second control group was 17 age-and gendermatched children with OM in whom no tumor was found. They were matched with the POM patients with respect to age, 
Scoring of Neurologic Status
Each child with POM or OM/no tumor was videotaped. A trained observer (E.D.T.) unaware of the child's treatment status rated motor impairment using the OM Evaluation Scale, which we devised and validated. 9 Each item of the 12-item scale was rated from 0 to 3 as an index of increasing neurologic severity or impairment. Total score was calculated as the sum of subscores, with a score of 36 indicating maximum abnormality.
Flow Cytometry
Whole peripheral blood samples (100 mL/tube) were stained with various panels of directly conjugated monoclonal antibodies ( Table 2) . We have implemented a broad panel of lymphocyte markers, designed previously to explore different potential mechanisms of pathophysiology, including gd cells, an ''atypical'' T-cell, and NK cells, important to host tumor defenses. They were further incubated for 10 minutes with 100 mL/tube Optilyse B (Immunotech). One milliliter of water was subsequently added to each sample, and it was incubated for a final 10 minutes at room temperature. Appropriately labeled isotypes (IgG1) were used as internal controls.
Samples were acquired and analyzed by flow cytometry on a FACSCalibur cytometer equipped with a 488-nm argon/633-nm HeNe laser (Becton-Dickinson, San Jose, CA). For each antibody combination, 10,000 events were acquired and analyzed with CellQuest (Becton-Dickinson). Instrument calibration was monitored daily with Calibrite beads (BectonDickinson). Data were plotted as log versus log fluorescence.
Blood Lymphocyte Counts
Because the relative size of lymphocyte subsets is not always consistent with a change in the absolute size of the FIGURE 1. The relative size of PBMC subsets. Data are means 6 SEM. A, In both the POM and OM groups, the percentage of CD4+ T-cells was significantly lower than controls (CTR). B, In the subgroup of POM and OM patients who had received chemotherapy as tumor therapy, the percentage of CD8+ T-cells was higher. C, When the POM and OM groups were combined, the chemotherapy group showed significant increases in multiple lymphocyte subsets. Asterisk indicates statistical significance by t tests: *0.01 # P , 0.05, **0.001 # P , 0.01, ***0.0001 # P , 0.001, ****0.00001 # P , 0.0001. subset, 10 lymphocytes were counted in a separate blood sample on a Sysmex 9500 automated counter in the clinical laboratory. Counts were expressed as K/mm 3 . Data from our controls compared favorably with the literature.
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Statistical Analysis
Data were analyzed statistically by t tests or one-way analysis of variance (ANOVA) using the Statistical Analysis System. 13 Because the role of chemotherapy in POM is controversial-most tumors are low-stage and survival is excellent without it-we identified prior tumor chemotherapy for secondary analysis.
RESULTS
Lymphocyte Immunophenotype
The relative size of the CD4+ T-cell subset (Fig. 1) was significantly less in the POM patients (218%) compared with controls (P = 0.02, t test). The CD4/CD8 ratio ( Fig. 2) was 29% lower in the POM patients (P = 0.013). There was a trend toward a higher percentage of HLA-DR+ T-cells (+68%, P = 0.06) and CD8+ T-cells (+20%, P = 0.056). There were no significant changes in CD19+ B-cells, CD32 or CD3+ NK cells, gd T-cells, CD25+ T-cells, CD45RA+ T-cells, or CD45RO+ T-cells.
The absolute size of lymphocyte subsets in the POM patients (Fig. 3) showed a significant decrease in the number of CD4+ T-cells (241%, P = 0.031) and gd T-cells (244%, P = 0.023). There was a trend toward fewer CD3+ cells (P = 0.063), CD45RA+ T-cells (P = 0.054), and CD45RO+ T-cells (P = 0.088).
There were no significant differences between the POM and OM/no tumor groups. As in the POM patients, there was a significant reduction in the relative size of the CD4+ T-cell subset (217%, P = 0.013) and the CD4/CD8 ratio (232%, P = 0.0035) compared with controls. The percentage of CD8+ T-cells was significantly higher (1.3-fold, P = 0.012).
Relation to Clinical Variables
In the POM group, three principal clinical variables were evaluated: age (infant, toddler, preschool, school-age), duration (acute, intermediate, chronic), and severity (mild, moderate, severe). A significant relation to POM duration (Fig. 4) was found for the CD4/CD8 ratio (F 3,30 = 3.33, P = 0.033, ANOVA) and the percentage of CD3+CD8+ cells (F 3,30 = 3.43, P = 0.029), whereas for the percentage of CD3+CD4+ cells, it was only a trend (F 3,30 = 2.75, P = 0.059). Similar relations were found for the OM/no tumor group. For the relative size of lymphocyte subsets in the POM patients, there was only a trend between the percentage of CD3+DR+ cells and severity (F 2,30 = 5.2, P = 0.099, ANOVA). There was a trend toward a reciprocal relation between severity and the percentage of CD4+ T-cells (F 3,30 = 2.42, P = 0.085) and the CD4/CD8 ratio (F 3,30 = 2.46, P = 0.082).
Effect of Chemotherapy
Prior tumor chemotherapy (see Fig. 1 ) was associated with a significant increase in the relative size of the CD3+CD8+ subset (+34%, P = 0.0032) and in HLA-DR+ T-cells (2.4-fold, P = 0.017). However, these changes were not reflected in the absolute size of the lymphocyte subsets (see Fig. 3 ). The CD4/CD8 ratio was lower in the POM patients who had received chemotherapy, whether based on the relative (243%, P = 0.011) or absolute (263%, P = 0.0093) size of lymphocyte subsets.
In patients with POM who had received chemotherapy, there was a negative correlation between prior tumor chemotherapy and the percentage of CD3+CD8+ cells (r = 20.51, P = 0.035) and a positive correlation with the CD4/CD8 ratio (r = 0.61, P = 0.0088). A positive correlation was found between prior tumor chemotherapy and the number of CD4+ cells (r = 0.49, P = 0.066) and NK+ cells (r = 0.58, P = 0.023). Due to the relatively small number of patients, multivariate analysis to look at the influence of chemotherapy was not possible.
There were no significant differences between the POM and OM/no tumor groups. In the OM group, chemotherapy was associated with a larger size of the CD8+ T-cell subset (1.6-fold, P = 0.00082) and a lower CD4/CD8 ratio (251%, P = 0.011). There was a trend toward a reduced percentage of CD4+ T-cells (P = 0.048) and an increased percentage of CD3+ NK cells (P = 0.052). The absolute number of CD4+ T-cells was lower (P = 0.018).
Given the lack of significant differences between the POM and OM groups, we combined the groups to increase sample size for another analysis to resolve whether statistical trends were real effects of chemotherapy. In the chemotherapy group, the relative subset size of CD3+ cells (P = 0.037), CD8+ T-cells (1.6-fold, P = 0.000016), gd+ T-cells (1.5-fold, P = 0.045), and HLA-DR+ T-cells (2.2-fold, P = 0.0029) was significantly larger. Both the relative (225%, P = 0.044) and absolute (261%, P = 0.034) size of the CD19+ B-cell pool was smaller. Also, the absolute size of the pool of CD4+ T-cells (243%, P = 0.0016) and CD32 NK cells (247%, P = 0.029) was smaller. The 46% reduction in the CD4/CD8 ratio was highly significant (P = 0.00015).
Tumor chemotherapy did not significantly reduce neurologic severity in the POM patients (see Table 1 ). In the OM group, there was a trend toward a reduction in total score (P = 0.057). When the POM group was combined with the OM group, there was no significant effect of chemotherapy.
Effect of Other Therapies
When chemotherapy-treated patients were excluded, the number of children with POM who had been treated with immunotherapy was too small for analysis by type of treatment (e.g., ACTH, IVIG, or steroids). Because there were no significant differences between the POM and OM groups, we combined them and compared all immunotherapy-treated children (n = 9) to controls. There were no statistically significant differences in PBMC subsets. The sample size was insufficient to reliably compare monotherapy and combination therapy.
DISCUSSION
This study identified abnormalities of lymphocyte distribution in peripheral blood from children with POM. Both the relative and absolute size of the CD4+ T-cell subset was significantly lower, as was the CD4/CD8 ratio. Because there were no significant differences between the POM and OM without tumor groups, these abnormalities are attributable to OM rather than neuroblastoma. We are aware of no previous studies and only two case reports in which blood lymphocytes were immunophenotyped in OM. A low CD4/CD8 ratio of 0.7 FIGURE 3. The absolute size of PBMC subsets. Data are means 6 SEM. A, In POM patients, the number of CD3+CD4+ cells and gd+ T-cells was significantly lower than controls (CTR), but the differences did not reach significance in the OM group. There was a trend toward lower CD45RA+ and CD45RO+ T-cells. B, Prior tumor chemotherapy in POM patients was not associated with significant changes. C, When the POM and OM groups were combined, the chemotherapy group showed significant decreases in CD4+ T-cells, CD32 NK cells, and CD19+ B-cells. Asterisk signifies statistical significance by t tests: *0.01 # P , 0.05, **0.001 # P , 0.01.
